Jyong Biotech (MENS) Current Leases (2024 - 2025)
Jyong Biotech's (MENS) quarterly Current Leases came in at $81000.0 in Q4 2025, down 49.06% year-on-year from $159000.0 in Q4 2024, and down 38.17% quarter-over-quarter from $131000.0 in Q2 2025.
Jyong Biotech (MENS) Current Leases (2024 - 2025) Analysis & Trends
Jyong Biotech's Current Leases history runs 2 years deep, the most recent figure standing at $81000.0 for Q4 2025.
- On a quarterly basis, Current Leases fell 49.06% year-over-year to $81000.0 in Q4 2025; TTM through Dec 2025 was $81000.0, a 49.06% decrease from a year earlier, with the FY2025 full-year figure at $81000.0, down 49.06% from the prior year.
- Current Leases retreated to $81000.0 in Q4 2025 per MENS's latest filing, from $131000.0 in the prior quarter.
- Across five years, Current Leases topped out at $159000.0 in Q4 2024 and bottomed at $81000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 81,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 81,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Dec 31, 2024 | 159,000.00 |